Cytokines and therapeutic oligonucleotides.
Therapeutic oligonucleotides - short strands of synthetic nucleic acids - encompass antisense and aptamer oligonucleotides. Antisense oligonucleotides are designed to bind to target RNA by complementary base pairing and to inhibit translation of the target protein. Antisense oligonucleotides enable specific inhibition of cytokine synthesis. In contrast, aptamer oligonucleotides are able to bind directly to specific proteins. This binding depends on the sequence of the oligonucleotide. Aptamer oligonucleotides with CpG motifs can exert strong immunostimulatory effects. Both kinds of therapeutic oligonucleotides - antisense and aptamer oligonucleotides - provide promising tools to modulate immunological functions. Recently, therapeutic oligonucleotides have moved towards clinical application. An antisense oligonucleotide directed against the proinflammatory intercellular adhesion molecule 1 (ICAM-1) is currently being tested in clinical trials for therapy of inflammatory disease. Immunostimulatory aptamer oligonucleotides are in preclinical development for immunotherapy. In the present review we summarize the application of therapeutic oligonucleotides to modulate immunological functions. We include technological aspects as well as current therapeutic concepts and clinical studies.
Hartmann
G
G
Medizinische Klinik, Klinikum Innenstadt of the Ludwig-Maximilians-University, Munich, Germany.
Bidlingmaier
M
M
Eigler
A
A
Hacker
U
U
Endres
S
S
D000818:Animals; D016207:Cytokines / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D009841:Oligonucleotides / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*
D016207:Cytokines; D009841:Oligonucleotides